Synthorx Inc Is A Biotechnology Company Based In La Jollacaliforniafocused On Developing Innovative Therapies For Cancer And Autoimmune Disordersoriginally Incorporated In Delaware In 2014The Company Utilizes Its Proprietary Expanded Genetic Alphabet Platform Technology To Create Optimized Biologics Known As Synthorinsthese Proteins Are Designed With Novel Amino Acids To Enhance Their Pharmacological Properties The Company S Lead Product Candidatethor 707Is A Variant Of Recombinant Human Il 2Aimed At Treating Multiple Solid Tumor Typessynthorx Also Develops Other Synthorin Programs Targeting Key Cytokines Involved In Anti Tumor Responsesincluding Il 10 And Il 15 For Immuno Oncology Applicationsin 2020Synthorx Was Acquired By Sanofibecoming A Subsidiary To Further Expand Its Portfolio Of Therapiesthe Company Has Filed 31 Patents And Raised $79 Million In Funding Prior To Its Acquisition
